A Review of the Role of Anticoagulation in the Treatment of Peripheral Arterial Disease

Abstract

Peripheral arterial disease (PAD) is a major medical/surgical problem associated with high risk for coronary heart disease (CHD). Anticoagulation plays a significant role in the management of the PAD patient. However, evidence-based medicine supports only select anticoagulants, mainly antiplatelet agents. The available anticoagulant classes, their individual medications, and the mechanisms of action are described. Dextran 40, platelet glycoprotein (GP) IIb/IIIa receptor antagonists, direct thrombin (factor IIa, FIIa) inhibitors, and factor Xa (FXa) inhibitors do not, at this juncture, appear to have a significant role to play in the PAD patient. Aspirin has been used in PAD patients for a few decades, as has warfarin, but the role of warfarin is very limited. An attempt has been made to place each medication and its function in context all the way to the present with oral direct thrombin (FIIa) and FXa inhibitors described. These inhibitors may ultimately play an, as yet, undefined role in PAD. Specific use of anticoagulants in PAD patients is described and aspirin still stands out as a fundamental therapy. The thienopyridines, especially clopidogrel, have their established place and there is some evidence for benefit from the use of clopidogrel in dual therapy with aspirin. Dipyridamole, especially with aspirin as dual therapy, and cilostazol also have their evidence-based niches. The main role played by warfarin is for the patient with a vein graft in the arterial circulation. Heparin retains significant procedural importance. For now, Class I, Level of Evidence A center around aspirin for the PAD patient with clopidogrel, an alternative agent.

Keywords

anticoagulation - aspirin - cardiovascular disease - coronary artery - peripheral arterial disease - risk factors - thienopyridines

• References

• 1 Gillum RF. Peripheral arterial occlusive disease of the extremities in the United States: hospitalization and mortality. Am Heart J 1990; 120 (6 Pt 1) 1414-1418
• 2 Hirsch AT, Criqui MH, Treat-Jacobson D , et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286 (11) 1317-1324
• 3 Sukhija R, Aronow WS, Yalamanchili K, Peterson SJ, Frishman WH, Babu S. Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology 2005; 103 (3) 158-160
• 4 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56 (3) 624-632
• 5 Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72 (5) 1521-1525
• 6 Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl) 199S-233S
• 7 Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; 11 (11) CD001272
• 8 Hollopeter G, Jantzen HM, Vincent D , et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409 (6817) 202-207
• 9 Biondi-Zoccai G, Lotrionte M, Agostoni P , et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011; 150 (3) 325-331
• 10 Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev 2011; 19 (2) 95-100
• 11 Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127 (2, Suppl) 53S-59S
• 12 Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol 2006; 147 (Suppl. 01) S241-S251
• 13 Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143 (1-2) 1-13
• 14 Weyrich AS, Denis MM, Kuhlmann-Eyre JR , et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005; 111 (5) 633-642
• 15 Katakami N, Kim YS, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010; 121 (23) 2584-2591
• 16 Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9 (28) 2289-2302
• 17 Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008; 141 (6) 757-763
• 18 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 19 Shammas NW. Complications in peripheral vascular interventions: emerging role of direct thrombin inhibitors. J Vasc Interv Radiol 2005; 16 (2 Pt 1) 165-171
• 20 Patel MR, Mahaffey KW, Garg J , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 21 Granger CB, Alexander JH, McMurray JJ , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 22 Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1992; 102 (4, Suppl) 337S-351S
• 23 Robless P, Okonko D, Mikhailidis DP, Stansby G. Dextran 40 reduces in vitro platelet aggregation in peripheral arterial disease. Platelets 2004; 15 (4) 215-222
• 24 Dörffler-Melly J, Koopman MM, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005; (1) CD002071
• 25 Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47 (9) 2169-2180
• 26 Goldhaber SZ, Manson JE, Stampfer MJ , et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340 (8812) 143-145
• 27 Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355 (9201) 346-351
• 28 Alonso-Coello P, Bellmunt S, McGorrian C , et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl) e669S-690S
• 29 Wiviott SD, Braunwald E, McCabe CH , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
• 30 Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Ticagrelor—a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?. Med Sci Monit 2009; 15 (12) MS24-MS30
• 31 Held C, Asenblad N, Bassand JP , et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57 (6) 672-684
• 32 Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009; 361 (10) 940-942
• 33 Gurbel PA, Bliden KP, Butler K , et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120 (25) 2577-2585
• 34 Kazui M, Nishiya Y, Ishizuka T , et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (1) 92-99
• 35 Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57 (11) 1251-1263
• 36 Cassar K, Ford I, Greaves M, Bachoo P, Brittenden J. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg 2005; 92 (2) 159-165
• 37 Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. J Vasc Surg 2005; 42 (2) 252-258
• 38 Milani RV. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?. Catheter Cardiovasc Interv 2009; 74 (Suppl. 01) S7-S11
• 39 Visonà A, Tonello D, Zalunardo B , et al. Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. Blood Transfus 2009; 7 (1) 18-23
• 40 Money SR, Herd JA, Isaacsohn JL , et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27 (2) 267-274 , discussion 274–275
• 41 Shinohara Y, Katayama Y, Uchiyama S , et al; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9 (10) 959-968
• 42 What is peripheral arterial disease? National Heart Lung and Blood Institute. 2012 http://www.nhlbi.nih.gov/health/health-topics/topics/pad/printall-index.html . Accessed June 29, 2012.
• 43 Arfvidsson B, Lundgren F, Drott C, Scherstén T, Lundholm K. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159 (6) 556-560
• 44 Sarac TP, Huber TS, Back MR , et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28 (3) 446-457
• 45 Johnson WC, Williford WO. Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35 (3) 413-421
• 46 Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2011; (6) CD000536
• 47 Thompson JF, Mullee MA, Bell PR , et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Eur J Vasc Endovasc Surg 1996; 12 (1) 86-90
• 48 Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight heparin sufficiently?. Thromb Res 1988; 52 (5) 353-359
• 49 van Veen JJ, Maclean RM, Hampton KK , et al. Protamine reversal of low molecular weight heparin: clinically effective?. Blood Coagul Fibrinolysis 2011; 22 (7) 565-570
• 50 Norgren L. Swedish EnoxaVasc Study Group. Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? An open label prospective randomized controlled trial. J Vasc Surg 2004; 39 (5) 977-984
• 51 Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1 (8426) 415-419
• 52 Collaborative overview of randomised trials of antiplatelet therapy—II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308 (6922) 159-168
• 53 Bhatt DL, Fox KA, Hacke W , et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
• 54 Belch JJ, Dormandy J, Biasi GM , et al; CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52 (4) 825-833 , e1–e2
• 55 Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 2004; 10 (1) 9-18
• 56 Rutherford RB, Baker JD, Ernst C , et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26 (3) 517-538
• 57 Katz SG, Kohl RD. Does dextran 40 improve the early patency of autogenous infrainguinal bypass grafts?. J Vasc Surg 1998; 28 (1) 23-26 , discussion 26–27
• 58 Rooke TW, Hirsch AT, Misra S , et al; American College of Cardiology Foundation; American Heart Association; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. Catheter Cardiovasc Interv 2012; 79 (4) 501-531